Interleukin-17A (IL-17A): A silent amplifier of COVID-19 - 18/09/21



Abstract |
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | One of the hallmarks of COVID-19 is the cytokine storm that provokes systemic inflammation. |
• | Elevated levels of interleukin-17A (IL-17A) are associated to disease severity and progression. |
• | We propose IL-17A as a silent amplifier of the COVID-19 immune response and (potentially) related therapy. |
Abbreviations : ARDS, CD99, COVID-19, CRS, G-CSF, GM-CSF, GRO-α, ICAM-1, IL-, IL-R, ILC3s, IFN-γ, IP-10, MAIT, MCP-1, MIP-2, MMP-, NK, PDGF, PECAM-1, PMNs, SARS-CoV-2, Th, TNF-α, VEGF
Keywords : Cytokine storm, COVID-19, IL-17A, Immunotherapy, Th17
Plan
Vol 142
Article 111980- octobre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.